Sarah Verhoeff

53 [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to predict WW in mccRCC patients A B Figure 3 Kaplan Meier curve for WW and OS Figure 3A shows the Kaplan Meier curves for time under WW; median WW-period is 16.1 months (95%CI 9.0-31.7). Figure 3B shows the Kaplan Meier curves for the overall survival (OS); median OS: 54.8 months (95%CI 34.2-NA) Four out of 36 patients who required systemic treatment, also underwent radiotherapy or surgery of all target lesions and seven patients received only best supportive care. Four patients were not fit for systemic treatment; in three patients’ clinical deterioration was due to rapid disease progression, one patient because of comorbidity and age. Three other patients did not want treatment. Of the remaining 25 patients, in first line 17 were treated with angiogenesis inhibitors (e.g., sunitinib, pazopanib, interferon-bevacizumab) and 8 patients with (combination) immunotherapy. The treatment related PFS on first-line angiogenesis inhibitors was 10.6 months (95%C 6.1-15.0) and with (combination) immunotherapy 17.9 months (95%CI 14.221.7). Five patients are still on active first-line treatment. An overview per patient is provided in Supplementary Figure S2.) In total, 17 of 36 patients (47%) died following WW after a median time of 27.4 months from the end of WW (95%CI 22.1-NA). 3